

Recombinant Human TNFSF14/LIGHT/HVEM-L/CD258 Protein

Catalog No.: RP01336 Recombinant

Sequence Information

Species Gene ID Swiss Prot Human 8740 043557

Tags N-his

Synonyms

TNFSF14;CD258;HVEML;LIGHT;LTg

Product Information

Source Purification

HEK293 cells ≥ 95 % as

determined by SDS-PAGE.

Calculated MW Observed MW

19.05 kDa 20-25 kDa

Endotoxin

< 1 EU/µg of the protein by LAL method.

Formulation

Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.

Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact

<u>a</u>	400-999-6126
\bowtie	cn.market@abclonal.com.cn
$\overline{\mathfrak{S}}$	www.abclonal.com.cn

Background

LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LT β R), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble non-signaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+and CD8+T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.

Basic Information

Description

Recombinant Human TNFSF14/LIGHT/HVEM-L/CD258 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Asp74-Val240) of Human TNFSF14 (Accession $\#NP_003798.2$) fused with a $6\times$ His tag at the N-terminus.

Bio-Activity

Measured by its binding ability in a functional ELISA. Immobilized Human TNFSF14 at 2 μ g/mL (100 μ L/well) can bind Mouse HVEM with a linear range of 0.02-0.89 μ g/mL.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.


After reconstitution, the protein solution is stable at -20 $^{\circ}$ C for 3 months, at 2-8 $^{\circ}$ C for up to 1 week.

Avoid repeated freeze/thaw cycles.


Operational Notes

For your safety and health, please wear a lab coat and disposable gloves for handling.

Validation Data



Recombinant Human TNFSF14/LIGHT/HVEM-L/CD258 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



Immobilized Recombinant Human TNFSF14 at 2 µg/mL (100 µL/well) can bind Mouse HVEM with a linear range of 0.02-0.89 µg/mL.